Sydney, June 22, 2026, 02:04 AEST
- Cochlear closed Friday at A$118.14, up 3.37%, after advancing in every session last week.
- The shares gained 13.9% for the week against a 0.3% rise in the S&P/ASX 200, but remain about 63% below their 52-week high.
- The next scheduled full-year result is August 18. Published FY26 underlying profit guidance remains A$290 million to A$330 million.
Cochlear Limited heads into Monday’s Australian session with momentum that has been absent for much of 2026. The hearing-implant maker rose from A$103.75 on June 12 to A$118.14 on Friday, while its latest listed price-sensitive disclosure remains the April 22 trading update rather than a fresh earnings revision.
That is the central issue. The rebound looks large, but it follows an almost 41% one-day collapse to a decade low after April’s profit warning. Investors are testing whether that selloff overshot the likely earnings damage; they are not responding to new operating data.
Friday’s 3.37% rise was notable because the S&P/ASX 200 fell 0.92% to 8,828.7, dragged lower by a materials selloff led by BHP. Healthcare was among the stronger parts of the market. That relative performance points to bargain hunting and a rotation back into battered medical stocks, rather than a broad risk-on move.
More than 2.1 million Cochlear shares changed hands on Friday, well above normal turnover. The session also preceded an S&P/ASX 200 quarterly rebalance taking effect before Monday’s open; Cochlear was not among the additions or removals. The timing may have amplified institutional flows, so the heavy volume alone does not confirm a fundamental turn.
The published earnings baseline remains difficult. Cochlear cut FY26 underlying net profit — a company-adjusted measure that removes selected one-off items — to A$290 million-A$330 million from an earlier range of A$435 million-A$460 million. Management cited softer developed-market demand, possible Middle East receivable losses, weaker factory cost recovery, restructuring expenses and a stronger Australian dollar. Chief Executive Dig Howitt said adult hearing treatment was still viewed as “a discretionary intervention”, though he added: “We remain confident of our market leadership.”
The first-half figures show why the market remains divided. Revenue rose 1% to A$1.176 billion, while underlying profit fell 9% to A$194.8 million. Implant units increased 6%, but implant revenue was flat and fell 2% at constant currency — which removes foreign-exchange movements — partly because sales shifted towards lower-priced emerging-market products. More units without comparable revenue growth is the margin problem investors need to see repaired.
Competition does not stand still. Sonova-owned Advanced Bionics and MED-EL both sell cochlear implant systems globally. Cochlear’s Nexa rollout therefore needs to translate into sustained referrals, pricing and market share, rather than launch interest alone.
But the rebound could unravel if weak referrals and hospital constraints persist or cost reductions fail to offset lower production and pricing. After the April warning, Jarden analysts Steve Wheen and Tristan Maher called the downgrade “far worse than anticipated” and said the valuation “multiple is also at risk” — meaning investors may pay less for each dollar of future earnings. The Australian
The ASX cash market remained closed at 02:04 AEST, with normal trading due to begin around 10 a.m. Monday. The immediate test is whether demand remains after index-related flows subside. Holding near A$115-A$118 on more ordinary volume would make the rebound look firmer; a quick reversal would suggest positioning, not repaired earnings, drove much of last week’s move.
